TTC Oncology LLC

Wefunder Offering Ends This Sunday!

Dear Investors & Supporters,

Our Wefunder round is closing this Sunday, APR 30 @ 11:59 PM ET.

Though the Wefunder round is closing soon, TTC Oncology is just beginning it's journey forward — we are excited and delighted to bring you with us!

We sincerely thank each and every one of you for taking the time to learn more about how, together, we can revolutionize breast cancer treatment across the globe.

If you would like to invest further, and/or would like to share the opportunity with others, now is the time. Once this opportunity is gone, it is not likely that investors can participate further with such an incredible share structure.

For all investors, please check your Payment status by logging into Wefunder, clicking on your profile icon, and selecting "Portfolio." If you haven't finalized your funds yet, please do login and finalize your payment process.

We look forward to updating you on progress as we work to bring our Therapeutic Oral Capsule TTC-352 to market.

Thank you again for your support.

Sincerely,

The TTC Oncology Team
wefunder.com/ttc.oncology

What's next? TTC Post Wefunder Plans
----
On April 10th, 2023, TTC engaged the investment banking services of Exemplar Capital, LLC. Exemplar’s mandate is to undertake a Reg D (exemption 506c) offering on behalf of TTC. TTC is seeking to raise up to $15 million to support the Company’s phase II clinical trial. TTC has also extended requests for proposals to selected CRO’s (clinical research organizations) to undertake the phase II study. Importantly, the Company has significant support from the Phase I study.

Exemplar is a highly successful New York City based investment bank, which will provide additional investor reach, credibility, and support to the TTC offering. This will be TTC's first institutional raise and management felt it best to proceed with Exemplar Capital to lead the way.

We thank Wefunder and the investment community for your steadfast support and look forward to providing future updates on our path ahead.

Wefunder Round Closing Soon!

Hi Everyone,

Our Wefunder Round will be closing soon, on 4/30. If you would like to invest further, please do so now. If you haven't invested yet, now is the time! And if you have pledged an investment but have not yet setup your Payment, please do so by logging into Wefunder, clicking on your Profile icon in the upper right corner, then clicking on "Portfolio." Next to TTC Oncology, select "Finish Investment" to complete the steps, as shown below.

Now is an exciting time to invest in TTC Oncology as we are well positioned to support breast cancer patients across the globe with our revolutionary new therapy.

Thank you for your support.

Sincerely,

TTC Oncology LLC

INVEST AT: wefunder.com/ttc.oncology

ONLY 2 DAYS UNTIL OUR WEBINAR!!

Join us this Thursday for a Live Webinar to learn more about TTC's Life Changing Treatment & how you can support the mission to improve lives for breast cancer patients.

To join, simply login at the following link:

https://us05web.zoom.us/j/88394424827?pwd=SGhBOWhERmJoTTZrMVA5SnB3enl5Zz09

Feel free to invite others you feel might be interested in learning more and supporting TTC's life changing drug.

Words from one of our investors!

Read his full testimonial and learn more here: https://wefunder.com/ttconcology/buzz

"Advancements in A.I. are beginning to deliver breakthroughs in breast cancer screening by detecting the signs that doctors miss. So far, the technology is showing an impressive ability to spot cancer at least as well as human radiologists."

Read the full article here:

https://www.nytimes.com/2023/03/05/technology/artificial-intelligence-breast-cancer-detection.html?smid=nytcore-ios-share&referringSource=articleShare

This is big news that we don't want you to miss. Now more than ever, and in the years to come, TTC's ground breaking treatment can help millions of people who will be diagnosed with breast cancer.

"Advancements in A.I. are beginning to deliver breakthroughs in breast cancer screening by detecting the signs that doctors miss. So far, the technology is showing an impressive ability to spot cancer at least as well as human radiologists,"

Read the full article here:

https://www.nytimes.com/2023/03/05/technology/artificial-intelligence-breast-cancer-detection.html?smid=nytcore-ios-share&referringSource=articleShare

Join us for a TTC Oncology Live Webinar to learn more about TTC's Life Changing Treatment & how you can support the mission to improve lives for breast cancer patients.

This 40m presentation includes Q&A where you can ask questions.

To join, simply login at the following link:

https://us05web.zoom.us/j/88394424827?pwd=SGhBOWhERmJoTTZrMVA5SnB3enl5Zz09

Feel free to invite others you feel might be interested in learning more and supporting TTC's life changing drug.

As we celebrate women on we also need to further the fight for Breast Cancer Treatment options.

Current treatment for metastatic cancer is a frightful and dreadful experience. We have a solution but need your help. Learn more here: https://wefunder.com/ttconcology/

We are excited to collaborate with Lantern Pharma to expand the clinical development of drug candidate TTC-352!

Read the the full article here:

https://finance.yahoo.com/news/lantern-pharma-ttc-oncology-establish-130000446.html?guccounter=1

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352 DALLAS, February 27, 2023--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning ("ML") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today annou...

Check out our interview/conversation on Money Nation: https://www.youtube.com/watch?v=iH3Ql_cKds4

We have completed a Phase I trial at four clinical sites and now we need your help. We are seeking investment to complete Phase II.

Learn more and invest here: https://wefunder.com/ttconcology

"Money Nation"-TTC Oncology-Debra Tonetti[CSO]- Arek Dudek[CEO]-Ed Gardner-Breast Cancer Research Watch this most recent (2023) podcast interview between Debra Tonetti [Director and Chief Scientific Officer] / Arek Dudek [CEO], both of TTC Oncology LLC an...

Do you or someone you know have Breast Cancer?

It's time for a better treatment than toxic chemotherapy. We have a solution and need your help to make it available to the millions of people struggling.

Invest here: https://wefunder.com/ttconcology

Do you or someone you know have Metastatic Breast Cancer? As you know, the traditional solution is toxic chemotherapy. It is a frightful and dreadful experience.

We are developing a better option and you can help!

Learn more about TTC Oncology and invest here: https://wefunder.com/ttconcology

Do you or someone you know have Metastatic Breast Cancer? As you know, the traditional solution is toxic chemotherapy. It is a frightful and dreadful experience.

We are developing a better option and you can help!

Learn more about TTC Oncology and invest here: https://wefunder.com/ttconcology

We are so thankful for our donors! 🤍

Please consider being part of this groundbreaking advancement: https://wefunder.com/ttconcology

Breast cancer is the second leading cause of cancer death in women. The current treatment is toxic. We are developing a better treatment and YOU can help.

Get involved here: https://wefunder.com/ttconcology

Thank you Univeristy of Illinois - Cancer Center for the complimentary words!

"Debra Tonetti’s first clinical trial has not gone the way she anticipated. It’s gone much better.

Tonetti, PhD, a University of Illinois Cancer Center member, professor of pharmacology and interim head of the department of biopharmaceutical sciences, is testing a drug she helped developed with fellow UI Cancer Center member Greg Thatcher that has the potential to help women whose breast cancer has stopped responding to hormone therapy."

Read the full article here: https://cancer.uillinois.edu/so-far-first-times-a-charm-for-tonettis-initial-clinical-trial/
Learn more about TTC Oncology here: https://wefunder.com/ttconcology

breastcancertreatment

Do you or someone you know have Breast Cancer?

"A new type of breast cancer drug developed by researchers at the University of Illinois Chicago can help halt progression of disease and is not toxic, according to phase 1 clinical trials. The drug is specifically designed for women whose cancer has stopped responding to hormone therapy.

The results are published in the journal Breast Cancer Research and Treatment."

Thank you to EurekAlert for the feature. Read the full article here: https://www.eurekalert.org/news-releases/753521

Learn more about TTC Oncology here: https://wefunder.com/ttconcology

Breast cancer is the second leading cause of cancer death in women. (American Cancer Society)

We have a treatment option that is non-toxic and can change the lives of millions. Invest to help us bring this solution to market: https://wefunder.com/ttconcology

For those experiencing chemotherapy, it is a frightful and dreadful experience, and for the surrounding loved ones, it is extremely difficult to process.

There is a better treatment than chemotherapy and that is our non-toxic drug. Quality of life matters. For the millions of people who will suffer the pain of current breast cancer treatments, both in the US and across the globe, the market availability of TTC-352 can not come soon enough.

Invest today to change the lives of millions: https://wefunder.com/ttconcology

If you saw our previous post about our ties with Dr. V. Craig Jordan, you may be intrigued to know in addition to the honors and awards bestowed upon him by Her Majesty Queen Elizabeth II, his work and efforts include further recognition from the beloved Diana, Princess of Wales:

“Later, I was named the Diana, Princess of Wales, Professor of Cancer Research at Northwestern University, and Mrs. Lurie and the president of Northwestern did the honors of giving me my medal—the Diana, Princess of Wales Medal—which I’m permitted to wear on any occasion where I’m wearing academic dress. That’s the tradition. Whenever I receive honorary degrees, I wear the Diana, Princess of Wales Medal.” - Dr. Jordan

This was a letter to Dr. Jordan from Princess Diana. Dr. Jordan organized a breast cancer symposium at the Robert H. Lurie Comprehensive Cancer Center, and Princess Diana was the keynote speaker during her 3-day visit to Chicago.

You can read the full article on V. Craig Jordan here:
https://ascopost.com/issues/september-10-2022/v-craig-jordan-cmg-obe-phd-dsc-fmedsci-the-father-of-tamoxifen-recounts-a-life-of-adventure-and-science/

Help us revolutionize breast cancer treatment here: https://wefunder.com/ttconcology

Did you know one of our mentors, Dr. V. Craig Jordan, was honored by Princess Diana?

Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). He has been recognized by the elite and was a driving force in the early days of Debra Tonetti and TTC Oncology.

Learn more about TTC Oncology here: https://wefunder.com/ttconcology

If you or someone you know has Breast Cancer, this is something you need to hear about!

Thank you to for the feature! We are proud to be recognized.

Learn more about TTC Oncology and invest here: https://wefunder.com/ttconcology

Meet the TTC Oncology team - Klara, Joe, and Melody:⁠
⁠
Klara Czobor: Director of Development⁠
As an accomplished Pharmacoeconomics Analyst, Klara's specialties include competitive intelligence, pharmaceutical product marketing, developing targeted medical content, & high profile disease-state & branded clinical & pharmaceutical promotion materials.⁠
⁠
Joe Cunningham: Chief Financial Officer⁠
Joe is an Economist & investment banker, has raised over $5 billion, runs global public & private companies, led complex negotiations & deal structures -his pharma experience includes Healthcare Management (clinical trial data company), AXM Pharma & Gamma Pharma.⁠
⁠
Melody Pekarek: General Manager⁠
Melody is responsible for overseeing & supporting work performed in the lab through clinical trials, developing budgets, managing expenses, ensuring compliance of all development timelines, and support aspects of investor relations.⁠
⁠
In addition to our founders and CMO, we have a team that is experienced and determined to bring TTC-352 to market. ⁠
⁠
Be a part of this groundbreaking advancement here: https://wefunder.com/ttconcology

If you are someone you know has suffered from Breast Cancer, then this is worth the read.

We are honored to have the support of V. Craig Jordan, a scientist with American and British citizenship specializing in drugs for breast cancer treatment and prevention. He was an inspiration early on for TTC Oncology.

Who exactly is V. Craig Jordan?

The list of his credentials is impressively lengthy. Currently, he is Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University.

Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with anti-hormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs).

In 2019, Her majesty, Queen Elizabeth II, appointed V. Craig Jordan as Companion of the Most Distinguished order of St. Michael and St. George, honoring his extraordinary work in the development of selective estrogen receptor modulators, most notably tamoxifen.

Dr. Jordan's words about TTC Oncology: "TTC-352 provides a novel, non-toxic option for patients with hormone-refractory metastatic breast cancer."

You can read the full article on V. Craig Jordan here: https://ascopost.com/issues/september-10-2022/v-craig-jordan-cmg-obe-phd-dsc-fmedsci-the-father-of-tamoxifen-recounts-a-life-of-adventure-and-science/

Join us in the development of our groundbreaking advancement here: https://wefunder.com/ttconcology

Thank you Breast Cancer News (a Bio News brand) for the feature!

"TTC-352, an investigational oral treatment for patients with metastatic ER-positive breast cancer that no longer responds to hormone therapy, was found to be safe and tolerable at high dose in a Phase 1 clinical study..."

Read the article here: https://breastcancer-news.com/2020/09/17/ttc-352-safe-hormone-therapy-resistant-patients-phase-1-clinical-trial/

Learn more about TTC Oncology here: https://wefunder.com/ttconcology

Smiling because we are working on a new breast cancer drug that is NON-TOXIC!

We can't do it without you. Please visit our We Funder page and learn more about this groundbreaking advancement.

With your help, we can make this life-changing solution available to the millions of men and women who will be diagnosed with breast cancer in the years to come.

Learn more here: https://wefunder.com/ttconcology/